These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 31090589)

  • 1. Treat-to-target in axial spondyloarthritis: gold standard or fools' gold?
    Machado PM; Deodhar A
    Curr Opin Rheumatol; 2019 Jul; 31(4):344-348. PubMed ID: 31090589
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treat to Target in Axial Spondyloarthritis: What Are the Issues?
    Danve A; Deodhar A
    Curr Rheumatol Rep; 2017 May; 19(5):22. PubMed ID: 28386759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treat-to-target in spondyloarthritis: implications for clinical trial designs.
    Wei JC
    Drugs; 2014 Jul; 74(10):1091-6. PubMed ID: 24969316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treat-to-target strategy with secukinumab as a first-line biological disease modifying anti-rheumatic drug compared to standard-of-care treatment in patients with active axial spondyloarthritis: protocol for a randomised open-label phase III study, AScalate.
    Poddubnyy D; Hammel L; Heyne M; Veit J; Jentzsch C; Baraliakos X
    BMJ Open; 2020 Sep; 10(9):e039059. PubMed ID: 32998926
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis: results of the open-label, pragmatic, cluster-randomised TICOSPA trial.
    Molto A; López-Medina C; Van den Bosch FE; Boonen A; Webers C; Dernis E; van Gaalen FA; Soubrier M; Claudepierre P; Baillet A; Starmans-Kool M; Spoorenberg A; Jacques P; Carron P; Joos R; Lenaerts J; Gossec L; Pouplin S; Ruyssen-Witrand A; Sparsa L; van Tubergen A; van der Heijde D; Dougados M
    Ann Rheum Dis; 2021 Nov; 80(11):1436-1444. PubMed ID: 33958325
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treat-to-target dose reduction and withdrawal strategy of TNF inhibitors in psoriatic arthritis and axial spondyloarthritis: a randomised controlled non-inferiority trial.
    Michielsens CA; den Broeder N; van den Hoogen FH; Mahler EA; Teerenstra S; van der Heijde D; Verhoef LM; den Broeder AA
    Ann Rheum Dis; 2022 Oct; 81(10):1392-1399. PubMed ID: 35701155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of treat-to-target strategy studies in rheumatic diseases: A systematic review and meta-analysis.
    Hao Y; Oon S; Nikpour M
    Semin Arthritis Rheum; 2024 Aug; 67():152465. PubMed ID: 38796922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Go or no-go for treat-to-target in axial spondyloarthritis?
    Webers C; Been M; van Tubergen A
    Curr Opin Rheumatol; 2023 Jul; 35(4):243-248. PubMed ID: 37071063
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treat-to-Target in Axial Spondyloarthritis: Are we there yet?
    Aouad K; El-Zorkany B
    Mediterr J Rheumatol; 2022 Mar; 33(Suppl 1):137-141. PubMed ID: 36127927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Defining and managing flares in axial spondyloarthritis.
    Aouad K; Gossec L
    Curr Opin Rheumatol; 2022 Jul; 34(4):195-202. PubMed ID: 35699318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Do we need new trial designs in spondyloarthritis?
    Landewé RBM
    Semin Arthritis Rheum; 2019 Dec; 49(3S):S8-S10. PubMed ID: 31779854
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA.
    van der Heijde D; Dougados M; Landewé R; Sieper J; Maksymowych WP; Rudwaleit M; Van den Bosch F; Braun J; Mease PJ; Kivitz AJ; Walsh J; Davies O; Bauer L; Hoepken B; Peterson L; Deodhar A
    Rheumatology (Oxford); 2017 Sep; 56(9):1498-1509. PubMed ID: 28498975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ankylosing Spondylitis versus Nonradiographic Axial Spondyloarthritis: Comparison of Tumor Necrosis Factor Inhibitor Effectiveness and Effect of HLA-B27 Status. An Observational Cohort Study from the Nationwide DANBIO Registry.
    Glintborg B; Sørensen IJ; Østergaard M; Dreyer L; Mohamoud AA; Krogh NS; Hendricks O; Andersen LS; Raun JL; Kowalski MR; Danielsen L; Pelck R; Nordin H; Pedersen JK; Kraus DG; Christensen SR; Hansen IM; Esbesen J; Schlemmer A; Loft AG; Al Chaer N; Salomonsen L; Hetland ML
    J Rheumatol; 2017 Jan; 44(1):59-69. PubMed ID: 27909080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Defining the target: clinical aims in axial spondyloarthritis.
    Marzo-Ortega H; Gaffney KM; Gaffney K
    Rheumatology (Oxford); 2018 Aug; 57(suppl_6):vi18-vi22. PubMed ID: 30445481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Future of Axial Spondyloathritis Treatment.
    Maguire S; Sengupta R; O'Shea F
    Rheum Dis Clin North Am; 2020 May; 46(2):357-365. PubMed ID: 32340707
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of patients with ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA) from a single rheumatology clinic in New Delhi.
    Malaviya AN; Kalyani A; Rawat R; Gogia SB
    Int J Rheum Dis; 2015 Sep; 18(7):736-41. PubMed ID: 26172961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of biologic disease-modifying anti-rheumatic drugs targeting remission in axial spondyloarthritis: systematic review and meta-analysis.
    Cruz-Machado AR; Rodrigues-Manica S; Silva JL; Alho I; Coelho C; Duarte J; Florêncio C; Pimentel-Santos FM; Tavares-Costa J; Vieira-Sousa E
    Rheumatology (Oxford); 2020 Nov; 59(11):3158-3171. PubMed ID: 32696064
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment response and drug retention rates in 24 195 biologic-naïve patients with axial spondyloarthritis initiating TNFi treatment: routine care data from 12 registries in the EuroSpA collaboration.
    Ørnbjerg LM; Brahe CH; Askling J; Ciurea A; Mann H; Onen F; Kristianslund EK; Nordström D; Santos MJ; Codreanu C; Gómez-Reino J; Rotar Z; Gudbjornsson B; Di Giuseppe D; Nissen MJ; Pavelka K; Birlik M; Kvien T; Eklund KK; Barcelos A; Ionescu R; Sanchez-Piedra C; Tomsic M; Geirsson ÁJ; Loft AG; van der Horst-Bruinsma I; Jones G; Iannone F; Hyldstrup L; Krogh NS; Hetland ML; Østergaard M
    Ann Rheum Dis; 2019 Nov; 78(11):1536-1544. PubMed ID: 31431486
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Minimal disease activity in axial spondyloarthritis: the need of the hour and a proposal for development.
    Deodhar AA; Kumthekar A; Dubreuil M
    Curr Opin Rheumatol; 2017 Jul; 29(4):293-297. PubMed ID: 28376060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The term 'non-radiographic axial spondyloarthritis' is much more important to classify than to diagnose patients with axial spondyloarthritis.
    Deodhar A; Strand V; Kay J; Braun J
    Ann Rheum Dis; 2016 May; 75(5):791-4. PubMed ID: 26768406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.